Michael Lichtenberg (Arnsberg, Germany) discusses the results of the SUCCESS six-month all-comers registry with Vascular News at CIRSE 2024 after the late-breaking results were presented in the First@CIRSE session.
The real-world registry evaluated the SELUTION SLR™ PTA drug-eluting balloon (DEB; Cordis) in patients who are regularly seen in routine work. The first report showed that consistent haemodynamic, functional and clinical improvements were observed, associated with a 97.7% freedom from clinically driven target revascularisation (CD-TLR), in a cohort in which the mean baseline target lesion length was 128mm. Significantly, the registry included 25.8% of patients with chronic limb-threatening ischaemia (CLTI), and this subgroup was revealed to have a freedom from CD-TLR of 97%.
The SELUTION SLR PTA DEB is an 018 platform that works well to treat distal tibial artery disease lesions in CLTI patients, says Lichtenberg. He also emphasises that the technical success of the procedure benefited from no “wash-out phenomenon” or peripheral embolisation of the drug, which can have a detrimental effect on the outcomes for patients.
The SUCCESS study results, for the first time, help provide confidence that sirolimus works to treat both CLTI patients and claudicants, concludes Lichtenberg.
This video is sponsored by Cordis.
